Depression Studies
Major Depressive Disorder
Phase 2/3Active
Key Facts
Indication
Major Depressive Disorder
Phase
Phase 2/3
Status
Active
About Pacific Clinical Research Medical Group
Pacific Clinical Research Medical Group is a long-established, private clinical research site organization that conducts Phase II-IV clinical trials for pharmaceutical sponsors, predominantly in psychiatry and neurology. Its business model is service-based, generating revenue by contracting with sponsors to recruit patients, administer trial protocols, and collect data. The company operates from a single physical site in Southern California and leverages its experienced medical team to attract trial participants by offering complementary care and medication. It occupies a niche as an investigative site within the broader clinical trial ecosystem.
View full company profileTherapeutic Areas
Other Major Depressive Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| Accelerated Deep TMS Protocol | BrainsWay | FDA Cleared |
| ZURZUVAE (zuranolone) | Sage Therapeutics | Phase 3 |
| MDD Clinical Trials | Boston Clinical Trials | Not Specified (Typically Phase 2-3) |
| NMDAR Antagonist (GM-2505/Bretisilocin) | Gilgamesh Pharmaceuticals | Phase 2 |
| Neuroplastogen (GM-1020) | Gilgamesh Pharmaceuticals | Phase 2a |
| NA-901 | Biomed | Phase 2B/3 |
| SP-624 (Forvisirvat) | Arrivo BioVentures | Phase 2 |
| NBS System for MDD | Nexstim | Approved |
| Major Depressive Disorder Studies | Noesis Pharma Clinical Trials | Phase 2-4 |
| Neurotyping Platform for MDD | Universal Brain | Development |
| CLE-100 | Clexio Biosciences | Phase 2 |
| Proliv™Rx | Neurolief | Phase 2 |